InterMune, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Perceptive Advisors Continues To Buy Amicus, Likely Acquisition Soon
Article By: Scott Matusow
Thursday, December 4, 2014 2:06 PM EDT
Investor Joseph Edelman leads Perceptive Advisors and since 1999 the fund has returned an annualized 30.2%. Last year, the fund returned about 48%. Edelman works with six biotech analysts to find companies with potential large gains ahead.
In this article: ACAD, FOLD, ITMN, SRPT
Roche Wastes No Time, Acquires Intermune For $8.3 Billion Dollars
Article By: Terry Chrisomalis
Tuesday, August 26, 2014 4:19 PM EDT
Roche deal spurs merger and acquisition activity across the biotech industry.
In this article: RHHBY, ACHN, ITMN, ARWR, RXII
E Roche's $8.3 Billion Deal For InterMune
Video By: Peter George Psaras
Monday, August 25, 2014 10:43 AM EDT
Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.
In this video: AZN, PFE, RHHBY, ITMN
Roche To Acquire The Most Dominant Fibrotic Lung Disease Innovator InterMune And Deliver Hope To Patients Worldwide
Article By: Dr. Hung Tran
Monday, August 25, 2014 3:02 AM EDT
The Swiss Pharmaceutical Giant, Roche, has agreed to acquire InterMune Inc. for $8.3 billion in cash. InterMune (NASDAQ: ITMN) is a biopharmaceutical company, based in Brisbane California, specializing in the development and commercialization of medicine to treat fibrotic lung diseases.
In this article: ITMN
EC How Sanofi's Growth Strategy Will Catapult Afrezza Into A Blockbuster Drug
Article By: Dr. Hung Tran
Wednesday, August 20, 2014 7:28 AM EDT
The market has been confused regarding Mannkind's recent partnership with Sanofi to commercialize the company's lead drug, Afrezza. However, the deal is quite favorable under 360's integrated analysis.
In this article: GSK, SNY, ITMN, MNKD, REGN


Latest Tweets for $ITMN

No tweets yet!